Q&A: DUR-928 ‘well tolerated’ for NASH in Phase 1b study

Nonalcoholic steatohepatitis is a severe form of fatty liver disease that affects 3% to 5% of the population in the United States and currently no approved drugs are available for treatment, according to a press release from Durect Corporation.Durect announced positive data from a phase 1b trial of orally administered DUR-928 in NASH that demonstrated significant improvement in liver function. DUR-928 is reportedly the first endogenous epigenetic regulator that was clinically tested for difficult-to-treat liver diseases.Healio Gastroenterology spoke with Eric Lawitz, MD, from the Texas LiverRead More

Share on facebook
Share on twitter
Share on linkedin